Clinical trials: Neoadjuvant Treatment
Meningioma, Malignant
Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma
This research study is studying a drug as a possible treatment for High Grade Meningioma.
- Trial name
- NCT04728568
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Tiantan Hospital
Brain Metastases
Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
The purpose of this study is to study if giving radiation to a brain tumor (a procedure called radiosurgery) before neurosurgery (surgery to remove the tumor) will help to keep brain tissue healthy, while possibly eliminating the…
- Trial name
- NCT03163368
- Testing
- Neoadjuvant stereotactic radiosurgery, Neurosurgical resection
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Cedars-Sinai Medical Center
Sinusoidal Obstruction Syndrome, Colorectal Liver Metastases
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
The purpose of the study is to determine whether anticoagulant use (i.e. salicylates, clopidogrel, low-molecular weight heparin, or coumarin derivates) is able to prevent the development of the sinusoidal obstruction syndrome…
- Trial name
- NCT00885950
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Dermatofibrosarcoma Protuberans
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.
- Trial name
- NCT00243191
- Testing
- imatinib mesylate
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Gastric Cancer
The Efficacy and Safety of Benmelstobart for GC/EGC
The goal of this clinical trial is to evaluate the major pathological response (MPR) rate of locally advanced gastric cancer / gastroesophageal junction cancer treated with bemosumab combined with antiangiogenic drugs and…
- Trial name
- EASOBFGE (NCT06603974)
- Testing
- surgery, Benmelstobart, tegafur
- Volunteers
- 48 people
- Sponsor
- Xijing Hospital
Neuroblastoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00017368
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- 9 sites in United States, Australia
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
IIIA Stage Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer
Cancer has always been one of the leading causes of death in the world, and China is facing more and more severe challenges from cancer.
- Trial name
- Neo-Pre-IC (NCT04326153)
- Testing
- Sintilimab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Breast Cancer Female
Effects of Ketogenic Diet in Overweight and Obese Women With Breast Cancer
Breast cancer is the most common cancer type among women in Turkey and the world. Chemotherapy, surgery, radiotherapy, immunotherapy and hormone therapy are used in the treatment.
- Trial name
- NCT05234502
- Testing
- Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%), Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)
- Volunteers
- 56 people
- Sponsor
- Necmettin Erbakan University
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
Esophageal Neoplasms, Carcinoma, Squamous Cell
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.
- Conditions
- Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00368329
- Testing
- Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Brain Metastasis
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.
- Trial name
- NCT01727531
- Testing
- Chloroquine diphosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Main Line Health
Estrogen Receptor Negative, HER2/Neu Negative
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
- Trial name
- NCT02744053
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Scintimammography
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
To purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (PD-1 / PD-L1) combined with chemotherapy for locally advanced thoracic esophageal squamous cellcarcinoma.
- Trial name
- NICCE (NCT05028231)
- Testing
- Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
HER2 Positive Esophagogastric Cancer
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
With improvements in response rate and survival seen for HER2 positive patients treated with HER2 blockade in the metastatic setting, the use of HER2 blockade in the neoadjuvant setting to increase antitumor effect shows promise.
- Trial name
- NCT01769508
- Testing
- 5-Fluorouracil, Oxaliplatin, Lapatinib
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- SCRI Development Innovations, LLC
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal…
- Trial name
- NCT03221426
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 171 sites in United States, Belgium and 22 more
- Volunteers
- 1,007 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Breast Cancer
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Primary Objective: Determination of pathologic complete response (pCR) rates Secondary Objective: Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain and troponin.
- Trial name
- NCT03329378
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Locally Advanced Head and Neck Squamous Cell Carcinoma
Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma
The dosing regimen in the trial group was: tirilizumab with albumin-bound paclitaxel and cisplatin for 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological…
- Trial name
- OPTimal (NCT06470217)
- Testing
- tirilizumab with albumin-bound paclitaxel and cisplatin, surgery
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Esophagus Cancer
Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma
Most ESCC received NAC in China without supportive evidence from local RCTs. The negative conclusion about NAC originated from Western countries in the 1990s.
- Trial name
- NCT05569668
- Testing
- Paclitaxel- and platinum-based chemotherapy
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Henan Cancer Hospital
Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia
Efficacy and Safety Study With MYL-1401H and Neulasta
This is a Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and Neulasta (Pegfilgrastim) in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.
- Trial name
- NCT02467868
- Testing
- MYL-1401H, Neulasta
- Where
- 36 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 193 people
- Sponsor
- Mylan Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.